Exane Derivatives’s Keysight KEYS Stock Holding History

Exane Derivatives’s Portfolio KEYS Stock Details KEYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-777	Closed	-$160K	–	1056
2021 Q4	$160K	Buy	+777	New	+$145K	0.04%	373

Other funds holding KEYS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Exane Derivatives's KEYS Position: Q1 2022 in Review

Exane Derivatives sold out of Keysight (KEYS) in Q1 2022, closing a stake of 777 shares — an estimated $160K sold.

Exane Derivatives first reported a position in KEYS in Q4 2021 and held it in 1 quarter. The position peaked at $160K in Q4 2021. 858 funds tracked by Wall St. Rank hold KEYS as of Q1 2022.

Exane Derivatives reported no remaining Keysight position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 777 Keysight shares in Q1 2022, an estimated $160K.
Exane Derivatives first reported a position in Keysight in Q4 2021 and held it in 1 quarter.
Exane Derivatives's Keysight position peaked at $160K in Q4 2021.
858 funds tracked by Wall St. Rank held Keysight as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.